Sequana Medical First Half 2024 Earnings: Revenues Beat Expectations, EPS Lags

Sequana Medical (EBR:SEQUA) First Half 2024 Results

Key Financial Results

• Net loss: €11.1m (loss narrowed by 33% from 1H 2023).
• €0.34 loss per share (improved from €0.65 loss in 1H 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sequana Medical Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 5.5%. Earnings per share (EPS) missed analyst estimates by 127%.

Looking ahead, revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Medical Equipment industry in Europe.

Performance of the market in Belgium.

The company's shares are down 24% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 7 warning signs with Sequana Medical (at least 5 which are significant), and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.